Healthcare Industry News: crush
News Release - January 5, 2010
Synovis Life Technologies to Distribute GEM SuperFine MicroClip Globally
Synovis MCA Launching Product at January 6-12 Microsurgical ConferencesST. PAUL, Minn.--(HSMN NewsFeed)--Synovis Life Technologies, Inc. (Nasdaq: SYNO ), a leading biomaterial and surgical products company, announced today that its wholly owned subsidiary, Synovis Micro Companies Alliance, Inc. (Synovis MCA), has received exclusive worldwide distribution rights to sell the GEM™ SuperFine™ MicroClip™. This new product is the smallest clip on the market today and is designed to stop bleeding during surgical procedures. Microsurgeons will use the GEM SuperFine MicroClip in various specialties – plastic and reconstructive, head and neck, orthopedic and hand – in procedures ranging from breast reconstruction to tissue grafts following cancer surgery and the reattachment or repair of fingers and limbs.
“Technological advances allow surgeons to work on smaller and smaller anatomical structures,” said Richard W. Kramp, Synovis Life Technologies president and chief executive officer. “The GEM SuperFine MicroClip keeps pace with changing needs in the microsurgical market and furthers Synovis MCA’s goal of serving as ‘The Microsurgeon’s Most Trusted Resource™’.”
The GEM SuperFine MicroClip is made of pure, annealed titanium for a malleable consistency that allows for zero memory which prevents the tip from opening after application. The clip is biologically inert, and the non-ferrous titanium is safe for use with MRI or related scanning equipment. The unique chevron shape of the GEM SuperFine MicroClip provides progressive and encompassing tip-to-tip closure for secure vessel occlusions. The diamond shape grooving and interlocking atraumatic teeth on the clip’s inner surface ensure a firm multi-direction non-crushing grip. Additionally, the ergonomically designed cartridge includes an adhesive backing for precise and effortless clip loading.
Synovis MCA currently distributes the GEM MicroClip, which has been very well received by customers, through its U.S. sales force and distributors around the world. The GEM SuperFine MicroClip, which is 35 percent smaller than the GEM MicroClip, is an extension of this product line.
Synovis MCA will showcase the GEM SuperFine MicroClip at the Annual Scientific Meetings of the American Society for Reconstructive Microsurgery (ASRM), American Association for Hand Surgery (AAHS), and American Society for Peripheral Nerve (ASPN) to be held concurrently January 6-12, 2010, in Boca Raton, Florida.
About Synovis Life Technologies
Synovis Life Technologies, Inc., based in St. Paul, Minn., develops, manufactures and markets mechanical and biological products used by several surgical specialties for the repair of soft tissue damaged or destroyed by disease or injury. The company’s products are designed to reduce risks and/or facilitate critical surgeries, improve patient outcomes and reduce healthcare costs. For additional information on Synovis Life Technologies and its products, visit the company’s Web site at www.synovislife.com.
Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as “should”, “could”, “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “continue”, or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include the timing of product introductions, the ability of our expanded direct sales force to grow revenues, outcomes of clinical and marketing studies as well as regulatory submissions, the number of certain surgical procedures performed, the ability to identify, acquire and successfully integrate suitable acquisition candidates (such as the recently acquired Orthopedic and Woundcare products), any operational or financial impact of the current global economic downturn, as well as the other factors found in the company’s reports to the Securities and Exchange Commission, including on the company’s Annual Report on Form 10-K for the year ended October 31, 2009.
Source: Synovis Life Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
